Université Lille, CNRS, Inserm, CHU Lille, UMR9020-UMR1277 - CANTHER - Cancer Heterogeneity, Plasticity and Resistance to Therapies, Lille, France.
Centre de Biopathologie, Lille CHU, Lille, France.
Mol Cancer Res. 2021 Apr;19(4):612-622. doi: 10.1158/1541-7786.MCR-20-0462. Epub 2021 Jan 20.
The mechanisms whereby the Hippo pathway effector YAP regulates cancer cell stemness, plasticity, and chemoresistance are not fully understood. We previously showed that in 5-fluorouracil (5-FU)-resistant colorectal cancer cells, the transcriptional coactivator YAP is differentially regulated at critical transitions connected with reversible quiescence/dormancy to promote metastasis. Here, we found that experimental YAP activation in 5-FU-sensitive and 5-FU-resistant HT29 colorectal cancer cells enhanced nuclear YAP localization and the transcript levels of the retinoic acid (RA) receptors RARα/γ and RAR target genes , and through RA Response Elements (RARE). In these two cell models, constitutive YAP activation reinforced the expression of the stemness biomarkers and regulators ALDH1A3, LGR5, and OCT4. Conversely, YAP silencing, RAR/RXR inhibition by the pan-RAR antagonist BMS493, and vitamin A depletion downregulated stemness traits and self-renewal. Regarding the mechanisms engaged, proximity-dependent labeling, nuclear YAP pulldown coupled with mass spectrometry, and chromatin immunoprecipitation (ChIP)/re-ChIP experiments revealed: (i) the nuclear colocalization/interaction of YAP with RARγ and RXRs; and (ii) combined genomic co-occupancy of YAP, RARα/γ, and RXRα interactomes at proximal RAREs of and promoters. Moreover, activation of the YAP/RAR-RXR cross-talk in colorectal cancer cells promoted RAR self-activation loops via vitamin A metabolism, RA, and active RAR ligands generated by ALDH1A3. Together, our data identify YAP as a bona fide RAR-RXR transcriptional coactivator that acts through RARE-activated stemness genes. IMPLICATIONS: Targeting the newly identified YAP/RAR-RXR cross-talk implicated in cancer cell stemness maintenance may lead to multitarget combination therapies for patients with colorectal cancer.
Hippo 通路效应因子 YAP 调控癌细胞干性、可塑性和化疗耐药性的机制尚不完全清楚。我们之前的研究表明,在氟尿嘧啶(5-FU)耐药的结直肠癌细胞中,转录共激活因子 YAP 在与可逆静止/休眠相关的关键转变中受到差异调控,以促进转移。在这里,我们发现实验性 YAP 激活可增强 5-FU 敏感和耐药 HT29 结直肠癌细胞中的核 YAP 定位以及维甲酸(RA)受体 RARα/γ 和 RAR 靶基因 和 的转录水平,这是通过 RA 反应元件(RARE)实现的。在这两种细胞模型中,组成型 YAP 激活增强了干性生物标志物和调控因子 ALDH1A3、LGR5 和 OCT4 的表达。相反,YAP 沉默、泛 RAR 拮抗剂 BMS493 抑制 RAR/RXR 以及维生素 A 耗竭下调了干性特征和自我更新。关于涉及的机制,邻近依赖性标记、核 YAP 下拉与质谱联用以及染色质免疫沉淀(ChIP)/再 ChIP 实验揭示:(i)YAP 与 RARγ 和 RXRs 的核共定位/相互作用;和(ii)YAP、RARα/γ 和 RXRα 相互作用组在 和 启动子近端 RARE 上的组合基因组共占据。此外,YAP/RAR-RXR 交叉对话在结直肠癌细胞中的激活促进了 RAR 自身激活循环,这是通过 ALDH1A3 代谢、RA 和活性 RAR 配体产生的。总之,我们的数据确定 YAP 是真正的 RAR-RXR 转录共激活因子,它通过 RARE 激活的干性基因发挥作用。意义:靶向新发现的与癌症细胞干性维持相关的 YAP/RAR-RXR 交叉对话可能导致针对结直肠癌患者的多靶点联合治疗。